Non-Applicability of Regulations 32 of SEBI (LODR)
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs Ltd has submitted an undertaking to BSE confirming that SEBI Regulation 32 (which deals with reporting on the use of funds raised through public, rights, or preferential issues) does not apply to the company for the quarter ended 31st December 2025. Managing Director Nanjappan Aravind certified that the company did not raise any funds through public issues, rights issues, or preferential issues during the quarter. This is a routine quarterly compliance filing submitted by the company.
No impact on shareholders or stock price. This is a standard procedural filing confirming that a specific SEBI disclosure rule does not apply to the company because it did not raise capital through public or preferential routes during the quarter.